Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Renin receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    49 result(s) found for: Renin receptor. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2012-000250-55 Sponsor Protocol Number: RASQAL Start Date*: 2012-07-12
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für innere Medizin III
    Full Title: Renin-Angiotensin System Quantification in patients treated with Aliskiren or Candesartan (RASQAL)
    Medical condition: - Chronic kidney disease stages III-IV (defined by MDRD formula) - Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003568-20 Sponsor Protocol Number: RGR Start Date*: 2008-08-08
    Sponsor Name:Prof Alice Stanton
    Full Title: Renin Genotype and Response to Renin Angiotensin System Blockade.
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004460-66 Sponsor Protocol Number: KARAASS-1 Start Date*: 2014-04-01
    Sponsor Name:Jørgen Jeppesen
    Full Title: Oral potassium supplementation in healthy men - interactions with the renin-angiotensin-aldosterone system and the sympathetic nervous system
    Medical condition: Blood pressure regulation and hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004866 10008393 Change in blood pressure LLT
    16.1 100000004865 10053967 Potassium supplementation LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-007881-45 Sponsor Protocol Number: SPP100ANL02T Start Date*: 2009-03-12
    Sponsor Name:University Medical Center Groningen
    Full Title: A double-blind, placebo-controlled, randomized trial investigating the safety and efficacy of Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients w...
    Medical condition: Patients with chronic heart failure and reduced glomerular filtration rate.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038443 Renal failure and impairment HLT
    9.1 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016902-17 Sponsor Protocol Number: CLINMEDINT001 Start Date*: 2012-05-18
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
    Full Title: Direct renin inhibitor (aliskiren)and carotid plaques instability markers in hypertensive patients requiring carotid endoarterectomy
    Medical condition: Essential hypertension.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059238 LLT
    9.1 10007692 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2013-002037-38 Sponsor Protocol Number: NL44415.078.13 Start Date*: 2013-10-29
    Sponsor Name:
    Full Title: The effect of correction of metabolic acidosis in chronics kidney disease on intrarenal RAS activity.
    Medical condition: Metabolic acidosis in chronic kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000362-39 Sponsor Protocol Number: CSPP100A2243 Start Date*: 2005-06-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, parallel-group, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the renoprotective effect of renin inhibition with Aliskiren as an a...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-000452-14 Sponsor Protocol Number: FARM537JNE Start Date*: 2007-08-29
    Sponsor Name:CONSORZIO MARIO NEGRI SUD
    Full Title: Long term impact of renin angiotensin system RAS inhibition on cardiorenal outcomes. A randomized controlled trial of cardio-renal effects of RAS inhibition in patients with cardio-renal risk. A...
    Medical condition: Patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027525 Microalbuminuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000361-19 Sponsor Protocol Number: CSPP100A2242 Start Date*: 2005-05-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, one-period, one-treatment study which objective is to evaluate the time course of the antiproteinuric and blood pressure lowering effect of renin inhibition with Aliskiren in patient...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-001900-17 Sponsor Protocol Number: 2020/0431/HP Start Date*: 2022-10-24
    Sponsor Name:DRCI - CHU de Rouen
    Full Title: PILOT STUDY OF THE EFFECT OF A SUBSTANCE P ANTAGONIST, APREPITANT, ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA AND ARTERIAL HYPERTENSION SYNDROME
    Medical condition: Patients with obstructive sleep apnea syndrome with arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10052741 Endocrine and metabolic secondary hypertension HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006861-18 Sponsor Protocol Number: 20061212 Start Date*: 2007-03-26
    Sponsor Name:Department of Cardiology
    Full Title: Comparison between beta-adrenergic blockers and angiotensin II receptor antagonists for the treatment of late hypertension in patients with repaired aortic coarctation
    Medical condition: Aortic coarctation and late hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002091-41 Sponsor Protocol Number: 03618 Start Date*: 2014-10-09
    Sponsor Name:Academisch medisch centrum
    Full Title: Right vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system
    Medical condition: To study the effect of losartan in adult patients with Tetralogy of Fallot and right ventricular dysfunction, defined as right ventricular ejection fraction <50%. Without severe valvular lesions.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015638-31 Sponsor Protocol Number: VitD-CHF Start Date*: 2010-03-22
    Sponsor Name:University Medical Center Groningen
    Full Title: An open-label, blinded-endpoint, randomized, prospective trial investigating the effects of vitamin D administration on plasma renin activity in patients with stable chronic heart failure.
    Medical condition: Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    12.0 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003175-19 Sponsor Protocol Number: U1111-1206-7541 Start Date*: 2019-11-28
    Sponsor Name:Steno Diabetes Center Copenhagen
    Full Title: Renal effects of treatment with Empagliflozin alone or in combination with Semaglutide in patients with type 2 diabetes and albuminuria - A double blinded, randomised, placebo controlled, parallel...
    Medical condition: Type 2 diabetes with renal complications
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001360-20 Sponsor Protocol Number: MINECRAFT Start Date*: 2021-07-29
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: MINECRAFT Study: MINEralcorticoid receptor antagonism with CanRenone As eFfective Treatment in moderate to severe ARDS in COVID-19, a phase 2 clinical trial.
    Medical condition: SARS-CoV2 infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001840-37 Sponsor Protocol Number: 2017-001840-37 Start Date*: 2019-01-15
    Sponsor Name:VU University Medical Center
    Full Title: ERtugliflozin triAl in DIabetes with preserved or reduced ejeCtion FrAcTion mEchanistic evaluation in Heart Failure: "ERADICATE-HF"
    Medical condition: Diabetes Mellitus Type 2 and Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003367-40 Sponsor Protocol Number: 2007/049/HP Start Date*: 2009-03-03
    Sponsor Name:CHU de Rouen
    Full Title: Pilot study of the effect of a substance P antagonist, aprepitant, on aldosterone and cortisol secretions in healthy volunteers
    Medical condition: The aim is to measure plasma aldosterone and cortisol concentrations in basal conditions and in response to different stimulation tests of the adrenal function
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001930-34 Sponsor Protocol Number: 170674-3479 Start Date*: 2005-11-25
    Sponsor Name:Department of Cardiology, Odense University Hospital
    Full Title: Left ventricular reverse remodelling after aortic valve replacement in severe valvular aortic stenosis - effect of blockade of the angiotensin-II receptor
    Medical condition: Patients with severe aortic valve stenosis treated with Aortic Valve Replacement (AVR)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002358-38 Sponsor Protocol Number: RET-D-001 Start Date*: 2015-04-28
    Sponsor Name:Travere Therapeutics, Inc.
    Full Title: PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED...
    Medical condition: FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004192-37 Sponsor Protocol Number: CRO1749 Start Date*: 2012-04-24
    Sponsor Name:Joint Research Compliance Office, Imperial College
    Full Title: Hellenic Anglo Research into Morning Or Night antihypertensive drug deliverY trial.
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 00:58:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA